Literature DB >> 20622677

Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.

Marlene Smurzynski1, Kunling Wu, Constance A Benson, Ronald J Bosch, Ann C Collier, Susan L Koletar.   

Abstract

BACKGROUND: AIDS-defining events (ADEs) decreased in the era of highly active antiretroviral therapy but still lead to hospitalizations and deaths. Understanding factors related to ADEs is important to mitigate events.
METHODS: We examined the relationship between demographics, behaviors, comorbidities, laboratory, clinical measurements, and ADEs diagnosed among subjects randomized to antiretroviral treatments (ART)/strategies and followed prospectively. Logistic regression models using generalized estimating equations generated odds ratios (ORs) focusing on the relationship between current CD4 T-cell count (CD4)/HIV-1 RNA viral load (VL) and ADEs in the subsequent 16-week study period.
RESULTS: Among the 2948 subjects in the analysis, overall incidence of ADEs was 1.53 per 100 person-years. Multivariate regression models adjusted for demographics, body mass index, and ADE history. A 6-level time-varying variable examined VL (>100,000 copies/mL, < or =100,000) at CD4 levels (0-50, 51-200, >200 cells/microL); reference level was CD4 >200/VL < or =100,000. Among ART naives, odds of having an ADE in the subsequent 16-week interval were greater among subjects with lower CD4 counts; this relationship was modified by VL level (CD4 < or =50/VL >100,000: OR 37.2; CD4 < or =50/VL < or =100,000: OR 30.5; CD4 51-200/VL >100,000: OR 13.0; CD4 51-200/VL < or =100,000: OR 4.5; all P values <0.001). Similar results were seen among ART-experienced subjects.
CONCLUSIONS: Recent CD4 and VL values are closely associated with development of ADEs even after examining a multitude of potential factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622677      PMCID: PMC2927805          DOI: 10.1097/QAI.0b013e3181e8c129

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  30 in total

Review 1.  HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines.

Authors:  John T Brooks; Jonathan E Kaplan; King K Holmes; Constance Benson; Alice Pau; Henry Masur
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

2.  Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study.

Authors:  R B D'Agostino; M L Lee; A J Belanger; L A Cupples; K Anderson; W B Kannel
Journal:  Stat Med       Date:  1990-12       Impact factor: 2.373

3.  AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.

Authors:  Marlene Smurzynski; Ann C Collier; Susan L Koletar; Ronald J Bosch; Kunling Wu; Barbara Bastow; Constance A Benson
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug

4.  Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.

Authors:  Janis V Giorgi; Robert H Lyles; Jose L Matud; Traci E Yamashita; John W Mellors; Lance E Hultin; Beth D Jamieson; Joseph B Margolick; Charles R Rinaldo; John P Phair; Roger Detels
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

5.  Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

Authors:  H R Brodt; B S Kamps; P Gute; B Knupp; S Staszewski; E B Helm
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

6.  Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.

Authors:  Rodger D MacArthur; George Perez; Sharon Walmsley; John D Baxter; Christopher M Mullin; James D Neaton
Journal:  HIV Clin Trials       Date:  2005 May-Jun

7.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

8.  Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.

Authors:  Kate Buchacz; Rose K Baker; Anne C Moorman; James T Richardson; Kathleen C Wood; Scott D Holmberg; John T Brooks
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

9.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

10.  Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy.

Authors:  Susan L Koletar; Paige L Williams; Julia Wu; J Allen McCutchan; Susan E Cohn; Robert L Murphy; Howard M Lederman; Judith S Currier
Journal:  Clin Infect Dis       Date:  2004-10-22       Impact factor: 9.079

View more
  9 in total

1.  Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.

Authors:  Supriya Krishnan; Jeffrey T Schouten; Denise L Jacobson; Constance A Benson; Ann C Collier; Susan L Koletar; Jorge Santana; Fred R Sattler; Ronald Mitsuyasu
Journal:  Oncology       Date:  2011-05-23       Impact factor: 2.935

Review 2.  Residual immune dysregulation syndrome in treated HIV infection.

Authors:  Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

3.  Women's Empowerment and HIV Testing Uptake: A Meta-analysis of Demographic and Health Surveys from 33 Sub-Saharan African Countries.

Authors:  Sanni Yaya; Gebretsadik Shibre; Dina Idriss-Wheeler; Olalekan A Uthman
Journal:  Int J MCH AIDS       Date:  2020-07-23

4.  The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.

Authors:  Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

5.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

Authors:  E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

6.  CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.

Authors:  Christopher J Hoffmann; Michael Schomaker; Matthew P Fox; Portia Mutevedzi; Janet Giddy; Hans Prozesky; Robin Wood; Daniela B Garone; Matthias Egger; Andrew Boulle
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

7.  Factors associated with remaining on initial randomized efavirenz-containing regimens.

Authors:  Marlene Smurzynski; Kunling Wu; Jeffrey T Schouten; Judith J Lok; Ronald J Bosch; Babafemi Taiwo; Victoria Anne Johnson; Ann C Collier
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

8.  A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy.

Authors:  Jennifer Gillis; Mona Loutfy; Ahmed M Bayoumi; Tony Antoniou; Ann N Burchell; Sharon Walmsley; Curtis Cooper; Marina B Klein; Nima Machouf; Julio S G Montaner; Sean B Rourke; Christos Tsoukas; Robert Hogg; Janet Raboud
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-15       Impact factor: 3.731

9.  Effect of AIDS-defining events at initiation of antiretroviral therapy on long-term mortality of HIV/AIDS patients in Southwestern China: a retrospective cohort study.

Authors:  Yunxuan Huang; Oulu Zhou; Zhigang Zheng; Yuexiang Xu; Yi Shao; Chunwei Qin; Fengxiang Qin; Jingzhen Lai; Huifang Liu; Rongfeng Chen; Li Ye; Hao Liang; Xionglin Qin; Junjun Jiang
Journal:  AIDS Res Ther       Date:  2020-07-17       Impact factor: 2.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.